Drugmaker Merck, moving to a brand new sales team structure inside the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a brand new chronic care sales force, the company said on Friday.
Three of Merck’s U.S. sales teams will be cut: primary care, disease-focused endocrinology as well as hospital chronic care, spokeswoman Claire Gillespie said in an emailed statement.
The aim is usually “to better support modifications in our business inside the United States,” she said.
The spokeswoman said Merck’s brand new chronic care team will focus on diabetes drug Januvia, as well as additional primary care products such as sleep medication Belsomra, as well as products for respiratory conditions as well as women’s health.
She noted of which Merck’s pipeline also has potential brand new candidates in primary care — for Alzheimer’s disease, asthma, chronic cough as well as heart failure.
Merck’s stock was little changed in midday trading on the brand new York Stock Exchange, at $63.78.
Earlier This kind of month, Merck said the idea would likely not seek regulatory approval for once-promising cholesterol drug anacetrapib after disappointing trial results.
Last month, the drugmaker discontinued developing an experimental drug combination for chronic hepatitis C, as competition rises as well as patient population shrinks. The company has previously written off an earlier hepatitis C program.
A major source of Merck’s growth has been the immunotherapy cancer drug Keytruda, which drew $881 million in second quarter revenue, more than double sales coming from the same quarter last year. of which’s second only to Januvia as well as Janumet, with $1.5 billion, down 8 percent coming from the same period the year before in part due to pricing pressure inside the U.S.
Merck is usually slated to report third-quarter financial results on Oct. 27.
additional pharmaceutical companies have also downsized. Eli Lilly & Co earlier This kind of month said the idea would likely lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year inside the development of two potential blockbuster drugs, works to cut costs.
Merck said none of the jobs being eliminated are being moved outside of the United States.
–CNBC’s Meg Tirrell contributed to This kind of report.